CARE currently collaborates with 19 German health insurers in colorectal cancer screening.
BERKELEY, Calif. and MAINZ, Germany, July 23, 2025 — Mainz Biomed N.V. (NASDAQ:MYNZ), a company focused on early cancer detection through diagnostics, has announced a partnership with CARE diagnostica Laborreagenzien GmbH (“CARE”).
CARE is currently collaborating with over 15 statutory health insurance companies on online screening programs using the fecal immunochemical test (FIT). The collaboration with Mainz Biomed will expand the range of services for risk groups to include the ColoAlert® test. This test uses molecular genetic analysis of stool biomarkers with PCR to improve detection rates, especially in early stages.
The cooperation, effective immediately, will help Mainz Biomed expand the distribution of ColoAlert® in Germany, aligning with the increasing demand for personalized screening solutions focused on early intervention.
Please follow us to stay up to date:
About Mainz Biomed NV
Mainz Biomed develops molecular genetic diagnostic solutions for life-threatening conditions that are ready for the market. ColoAlert®, the Company’s flagship product, is a precise, non-invasive, and user-friendly diagnostic test for the early detection of colorectal cancer. ColoAlert® is available in Europe and the United Arab Emirates. The Company is conducting a pivotal FDA clinical study for US regulatory approval. Mainz Biomed’s product candidate portfolio also features PancAlert, an early-stage pancreatic cancer screening test based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. For more information, visit or follow us on , and .
About CARE diagnostica Laborreagenzien GmbH
CARE diagnostica Laborreagenzien GmbH has been committed to quality and innovation in colorectal cancer screening in Germany for over 40 years. More information is available at .
For media inquiries
MC Services AG
Maximilian Schur / Simone Neeten
+49 211 529252 20
For investor inquiries, please contact
Forward-Looking Statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. These statements can be identified by terms such as “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project,” and similar expressions that predict or indicate future events or trends, or that are not statements of historical facts. These forward-looking statements reflect current analysis of existing information and are subject to risks and uncertainties. Therefore, caution should be taken when relying on forward-looking statements. Actual results may differ significantly from the Company’s expectations or projections due to known and unknown risks. Factors that could cause actual results to differ include: (i) failure to meet projected development and related targets; (ii) changes in applicable laws or regulations; (iii) the impact of the COVID-19 pandemic on the Company and its markets; and (iv) other risks and uncertainties described herein, as well as those discussed in the Company’s reports and public filings with the Securities and Exchange Commission (the “SEC”). More information about these and other factors that may affect the Company’s expectations and projections can be found in its filings with the SEC, including its annual report on Form 20-F filed on March 31, 2025. The Company’s SEC filings are available on the SEC’s website at www.sec.gov. Any forward-looking statement in this press release is based only on information currently available to Mainz Biomed and speaks only as of the date it is made. Mainz Biomed does not undertake any obligation to update any forward-looking statement, whether written or oral, due to new information, future developments, or otherwise, except as required by law.
